Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Molecular Genetics in Neurology
Ann Neurol 34:757-773, Martin,J.B., 1993
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Positron Computed Tomography for Studies of Myocardial & Cerebral Function
Ann Int Med 98:339-359, Phelps,M.E.,et al, 1983
Levels of y-Aminobutyric Acid in Cerebrospinal Fluid in Various Neurologic Disorders
Arch Neurol 37:352-355, Manyam,N.V.B.,et al, 1980
Huntington Disease: Clinical Features and Diagnosis
UptoDate Dec 2017, Oksana Suchowersky, 2017
Huntingtons Disease
BMJ 341:34-40, Novak,M.J. &Tabrizi,S.J., 2010
Functional Brain Changes in Presymptomatic Hunington's Disease
Ann Neurol 55:879-883, Reading,S.A.,et al, 2004
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Few Psychological Consequences of Presymptomatic Testing for Huntington Disease
Lancet 349:4, Bundey,S., 1997
Longitudinal Change in Basal Ganglia Volume in Patients with Huntington's Disease
Neurol 48:394-399, Aylward,E.H.,et al, 1997
CAG Repeat Number Governs the Development Rate of Pathology in Huntington's Disease
Ann Neurol 41:689-692, Penney,J.B.,et al, 1997
Hereditary Late-Onset Chorea Without Significant Dementia:Genetic Evid for Phenotypic Variation in Huntington's Disease
Neurol 45:443-447, Britton,J.W.,et al, 1995
The Prevention of Neurogenetic Disease
Arch Neurol 52:356-362, 3451995., Rosenberg,R.N.&Iannaccone,S.T., 1995
Juvenile Huntington Disease:CT and MR Features
AJNR 16:1405-1412, Ho,V.B.,et al, 1995
A Worldwide Study of the Huntington's Disease Mutation, The Sensitivity & Specificity of Measuring CAG Repeats
NEJM 330:1401-1406, 14501994., Kremer,B.,et al, 1994
Reduced Basal Ganglia Volume Associated with the Gene for Huntington's Disease in Asymptomatic at-Risk Persons
Neurol 44:823-828, Aylward,E.H.,et al, 1994
Trinucleotide Repeat Expansion in Neurological Disease
Ann Neurol 36:814-822, LaSpada,A.R.,et al, 1994
Clinical and Magnetic Resonance Features of the Classic & Akinetic-Rigid Variants of Huntington's Dis
Arch Neurol 50:17-19, Oliva,D.,et al, 1993
The Polymerase Chain Reaction:Application to Nervous System Disease
Ann Neurol 34:513-523, Darnell,R.B., 1993
Putamen Volume Reduction on Magnetic Resonance Imaging Exceeds Caudate Changes in Mild Huntington's Disease
Ann Neurol 31:69-75, Harris,G.J.,et al, 1992
The Psychological Consequences of Predictive Testing for Huntington's Disease
NEJM 327:1401-1405, 14491992., Wiggins,S.,et al, 1992
Serial Changes of Cerebral Glucose Metab & Caudate Size in Persons at Risk for Huntington's Dis
Arch Neurol 49:1161-1167, Grafton,S.T.,et al, 1992
Ideomotor Apraxia in Huntington's Disease
Arch Neurol 48:35-41, Shelton,P.A.&Knopman,D.S., 1991
Genetic Testing for Huntington's Disease
BMJ 300:1089-1090, Harper,P.,et al, 1990
Abnormalities of Striatal Projection Neurons and n-Methyl-d-Aspartate Receptors in Presymptomatic Huntington's Disease
NEJM 322:1293-1298, Albin,R.L.,et al, 1990
Predictive Testing for Huntington's Disease, Progress and Problems
BMJ 298:404-405, 1989, Harper,P.S.&Morris,M.J., 1989
Clinical-Pathologic Correlation in Huntington's Disease:A Neuropsychological and Computed Tomography Study
Neurol 39:796-801, Bamford,K.A.,et al, 1989
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986
Presymptomatic Testing for Huntington's Disease
JAMA 253:3286-3291, Bird,S.J., 1985
Bicaudate Index in Computerized Tomography of Huntington Disease & Cerebral atrophy
Neurol 28:1196-1200, Barr,A.N.,et al, 1978
Identification of GABA in Human CSF by Gas Liquid Chromatography & Mass Spectrometry
NEJM 296:692, Huizinga,J.D.,et al, 1977